Otsuka Pharmaceutical Co., Ltd.

September 28, 2022

Otsuka to Launch QuickNaviTM-Noro3, a Norovirus Antigen Quick Detection Kit
- Minimum detection sensitivity improved compared to QuickNaviTM-Noro2 -

Otsuka Pharmaceutical Co., Ltd. will launch the norovirus antigen test kit QuickNavi™- Noro3 to medical institutions across Japan. It is the latest product in the QuickNaviTM series of in vitro diagnostics. The kit, manufactured domestically by Denka Company Limited, will be co-marketed by the two companies from October 26. 

QuickNavi™-Noro3 is an assay kit for rapid and specific detection of norovirus antigen in feces using immunochromatography. There are multiple genotypes of norovirus, and compared to QuickNavi™-Noro 2, this product has improved sensitivity for a wide variety of genotypes, including those that have become prevalent in recent years. As with the conventional product, this kit does not require centrifugation or other pretreatment of specimens, and final determination of the presence or absence of the virus can be made within 15 minutes.